Patients with COVID-19 can require supplemental oxygen for acute hypoxemic respiratory failure. While international guidelines recommend a target SpO2 between 90-96%, a safe oxygenation strategy has not been identified. In this podcast, we discuss the recently published HOT-COVID Trial, which compared a lower oxygenation strategy with a higher oxygenation strategy in adult ICU patients with COVID-19.
Acute hypoxemic respiratory failure is a leading cause of ICU admission worldwide. Oxygen is first-line therapy for patients with acute hypoxemic respiratory failure and...
The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in...
Currently, there is no approved treatment or proven therapy for COVID-19. As such, many have turned to treatments with little to no supporting evidence....